Literature DB >> 33316538

U-RT1 - A new model for Richter transformation.

Teresa Schmid1, Julia Maier1, Melanie Martin1, Alpaslan Tasdogan2, Eugen Tausch3, Thomas F E Barth1, Stephan Stilgenbauer3, Johannes Bloehdorn3, Peter Möller4, Kevin Mellert1.   

Abstract

The advent of highly effective treatments targeting the disease biology of chronic lymphocytic leukemia (CLL) has transformed the therapeutic field tremendously. However, transformation into an aggressive B-cell lymphoma, called Richter syndrome (RS), remains highly challenging since the treatment options for this condition are still insufficient. Exploratory drug testing and experimental studies are restricted by the lack of satisfactory models. We have established U-RT1, a cell line derived from a highly proliferating RS clonally related to the patient's underlying CLL. The cell line shows morphological features and an immunophenotype of RS-DLBCL (non-GCB). Molecular analysis revealed a complex karyotype with driver aberrations characteristic for RS such as loss of TP53 and CDKN2A. Furthermore, U-RT1 displays a chromosomal gain of the NOTCH1 gene locus and strong immunoreactivity for BCL-2. These features suggest that U-RT1 is the first eligible model system for investigations on the pathogenesis of RS and novel treatment options.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CLL; DLBCL; In vitro model; Richter syndrome; Richter transformation

Year:  2020        PMID: 33316538     DOI: 10.1016/j.neo.2020.11.010

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  2 in total

1.  CARD9 Forms an Alternative CBM Complex in Richter Syndrome.

Authors:  Julia Maier; André Lechel; Ralf Marienfeld; Thomas F E Barth; Peter Möller; Kevin Mellert
Journal:  Cancers (Basel)       Date:  2022-01-21       Impact factor: 6.639

Review 2.  Biology and Treatment of Richter Transformation.

Authors:  Adalgisa Condoluci; Davide Rossi
Journal:  Front Oncol       Date:  2022-03-22       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.